Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LGALS7B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LGALS7B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LGALS7B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LGALS7B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
GO:00420988 | Cervix | CC | T cell proliferation | 49/2311 | 199/18723 | 1.32e-06 | 4.49e-05 | 49 |
GO:00224084 | Cervix | CC | negative regulation of cell-cell adhesion | 48/2311 | 196/18723 | 1.99e-06 | 6.18e-05 | 48 |
GO:00421297 | Cervix | CC | regulation of T cell proliferation | 43/2311 | 171/18723 | 3.21e-06 | 8.77e-05 | 43 |
GO:00706637 | Cervix | CC | regulation of leukocyte proliferation | 55/2311 | 245/18723 | 6.51e-06 | 1.56e-04 | 55 |
GO:00506705 | Cervix | CC | regulation of lymphocyte proliferation | 51/2311 | 225/18723 | 1.05e-05 | 2.32e-04 | 51 |
GO:0051250 | Cervix | CC | negative regulation of lymphocyte activation | 39/2311 | 157/18723 | 1.23e-05 | 2.57e-04 | 39 |
GO:00329444 | Cervix | CC | regulation of mononuclear cell proliferation | 51/2311 | 227/18723 | 1.36e-05 | 2.73e-04 | 51 |
GO:00706617 | Cervix | CC | leukocyte proliferation | 65/2311 | 318/18723 | 2.56e-05 | 4.32e-04 | 65 |
GO:0002695 | Cervix | CC | negative regulation of leukocyte activation | 43/2311 | 187/18723 | 3.47e-05 | 5.60e-04 | 43 |
GO:00466516 | Cervix | CC | lymphocyte proliferation | 59/2311 | 288/18723 | 5.53e-05 | 8.10e-04 | 59 |
GO:0050868 | Cervix | CC | negative regulation of T cell activation | 31/2311 | 122/18723 | 5.81e-05 | 8.46e-04 | 31 |
GO:00329435 | Cervix | CC | mononuclear cell proliferation | 59/2311 | 291/18723 | 7.51e-05 | 1.03e-03 | 59 |
GO:1903038 | Cervix | CC | negative regulation of leukocyte cell-cell adhesion | 33/2311 | 141/18723 | 1.90e-04 | 2.21e-03 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LGALS7B | SNV | Missense_Mutation | rs771820960 | c.136N>A | p.Asp46Asn | p.D46N | P47929 | protein_coding | tolerated(0.05) | possibly_damaging(0.858) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
LGALS7B | SNV | Missense_Mutation | rs771820960 | c.136G>A | p.Asp46Asn | p.D46N | P47929 | protein_coding | tolerated(0.05) | possibly_damaging(0.858) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LGALS7B | SNV | Missense_Mutation | rs762396841 | c.248G>A | p.Arg83His | p.R83H | P47929 | protein_coding | tolerated(0.31) | benign(0.005) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
LGALS7B | SNV | Missense_Mutation | rs770777524 | c.215N>A | p.Arg72His | p.R72H | P47929 | protein_coding | tolerated(0.16) | benign(0.009) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LGALS7B | SNV | Missense_Mutation | novel | c.131G>A | p.Gly44Asp | p.G44D | P47929 | protein_coding | tolerated(0.88) | benign(0.003) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
LGALS7B | SNV | Missense_Mutation | novel | c.322N>A | p.His108Asn | p.H108N | P47929 | protein_coding | deleterious(0.01) | possibly_damaging(0.816) | TCGA-5C-A9VH-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LGALS7B | SNV | Missense_Mutation | | c.96N>C | p.Arg32Ser | p.R32S | P47929 | protein_coding | tolerated(0.05) | possibly_damaging(0.476) | TCGA-DD-A1EL-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
LGALS7B | SNV | Missense_Mutation | novel | c.223N>T | p.Arg75Cys | p.R75C | P47929 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LG-A9QC-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LGALS7B | SNV | Missense_Mutation | novel | c.226N>A | p.Gly76Arg | p.G76R | P47929 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
LGALS7B | SNV | Missense_Mutation | | c.118N>T | p.Gly40Trp | p.G40W | P47929 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-EJ-7125-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |